Endocrinology (all articles)
Phase 2b RCT | Danuglipron, an oral GLP-1R agonist, reduces body weight and improves glycemic control in type 2 diabetes
1 Jun, 2023 | 12:17h | UTC
SR | Prevalence of clinical signs, symptoms and comorbidities at diagnosis of acromegaly
1 Jun, 2023 | 11:52h | UTC
M-A | Plant-based diets reduce key atherogenic lipoproteins
30 May, 2023 | 11:48h | UTCEditorial: Plant-based dietary patterns and atherogenic lipoproteins – European Heart Journal
Review | Child and adolescent obesity
30 May, 2023 | 11:45h | UTCChild and adolescent obesity – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Commentary on Twitter
A Primer in @DiseasePrimers discusses the epidemiology, mechanisms, diagnosis, prevention and management of obesity in children and adolescents, highlighting patient quality of life and areas for further research. https://t.co/Zpcb4RbH2J pic.twitter.com/uneXxVyTDg
— Nature Portfolio (@NaturePortfolio) May 28, 2023
Review | Managing menopausal symptoms, fertility, and bone health in breast cancer women on endocrine therapy
30 May, 2023 | 11:40h | UTC
Clinical Trial Update | Mesenteric defects closure in bariatric surgery cuts reoperation rate due to bowel obstruction
29 May, 2023 | 10:49h | UTCLong-term Safety and Efficacy of Closure of Mesenteric Defects in Laparoscopic Gastric Bypass Surgery: A Randomized Clinical Trial – JAMA Surgery (link to abstract – $ for full-text)
See also: Visual Abstract
A pragmatic approach to the management of menopause
25 May, 2023 | 11:30h | UTCA pragmatic approach to the management of menopause – Canadian Medical Association Journal
News Release: Managing menopause: Hormone therapy is back – Canadian Medical Association Journal
Review | Exercise training and revascularization in the management of symptomatic peripheral artery disease
25 May, 2023 | 11:23h | UTC
Commentary on Twitter
Exercise Therapy and Revascularization in the Management of Symptomatic Peripheral Artery Diseasehttps://t.co/Nywh4YxIs3 pic.twitter.com/K8z7E5eK9v
— Physio Meets Science (@PhysioMeScience) May 7, 2023
Graves’ disease in children: an update
25 May, 2023 | 11:18h | UTCGraves’ Disease in Children: An Update – Clinical Medicine Insights: Endocrinology and Diabetes
Guidelines on the diagnosis and treatment of foot infection in persons with diabetes
24 May, 2023 | 13:30h | UTC
RCT | Spironolactone enhances acne outcomes and offers a viable alternative to oral antibiotics
24 May, 2023 | 13:27h | UTCSummary: The SAFA (Spironolactone for Adult Female Acne) trial was a multicenter, phase 3, double-blind, randomized controlled trial in England and Wales and evaluated the efficacy of spironolactone for treating adult women with acne vulgaris. A total of 410 women, aged ≥18 years and suffering from facial acne for a minimum of six months, were randomly assigned to receive either 50 mg/day of spironolactone or a placebo, increasing to 100 mg/day until week 24.
The primary outcome was measured by the Acne-Specific Quality of Life (Acne-QoL) symptom subscale score at week 12 and 24. The trial demonstrated that spironolactone improved Acne-QoL scores more effectively than the placebo, particularly at week 24. Additionally, more participants in the spironolactone group reported acne improvement, and treatment success was significantly higher in this group at week 12. Mild side effects, notably headaches, were more common in the spironolactone group.
The findings from the SAFA trial highlight spironolactone’s effectiveness, safety, and tolerability in treating adult women with acne vulgaris, suggesting it is a viable alternative to long-term antibiotic treatments. Future research is proposed on higher initial dosages of spironolactone, and its effects on different subgroups like patients with different ages, body mass index, and ethnicity.
Editorial: What do we know about prescribing spironolactone for acne? – The BMJ
News Release: Non-antibiotic treatment for women with persistent acne shown to be effective – University of Southhampton
Review | Glycemic management in people with diabetes on peritoneal dialysis
24 May, 2023 | 13:04h | UTC
Commentary on Twitter (thread – click for more)
1/Hey #Nephtwitter #Medtwitter
Today, we are discussing
Clinical considerations while managing diabetes on Peritoneal dialysis (PD)#Tweetorial alert ?@KIReports
Full text link: https://t.co/sOEIa6AuNh pic.twitter.com/kVn4XDYylU— KIReports (@KIReports) May 20, 2023
Opinion Video | Questioning the reliability of nutrition science
23 May, 2023 | 13:02h | UTC
AHA Statement | Addressing diabetes and atherosclerosis in Asian American adults: insights, management, future steps
22 May, 2023 | 13:42h | UTCNews Release: Culture, diet, economic factors and more affect CVD risk among Asian Americans – American Heart Association
Commentary: Think Differently: Diabetes, CVD Risks in Asian Americans Not Uniform, AHA Says – TCTMD
Commentary on Twitter
Examining Asian American subgroups separately is crucial to understanding different mechanisms that contribute to T2D & ASCVD risks. The new scientific statement: https://t.co/taTVvXtXd2 @CircAHA @kwancardio @SallySWong @alka_kanaya @HeartDocSadiya @SvatiShah @FFR81 @hayman_ll pic.twitter.com/lWtl1AKBKg
— AHA Science (@AHAScience) May 8, 2023
Underdiagnosis of primary aldosteronism: a review of screening and detection
22 May, 2023 | 13:40h | UTC
Commentary on Twitter
Underdiagnosis of Primary Aldosteronism: A Review of Screening and Detection https://t.co/PYzSCZD2L7 (FREE)@MarioFunesMD @BhallaResearch @StanfordNeph pic.twitter.com/k7intLqpK3
— AJKD (@AJKDonline) May 19, 2023
RCT | Once-weekly insulin icodec shows non-inferiority to daily insulin glargine in type 2 diabetes patients
18 May, 2023 | 13:48h | UTCSwitching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial – The Lancet (link to abstract – $ for full-text)
WHO advises not to use non-sugar sweeteners for weight control in newly released guideline
16 May, 2023 | 15:04h | UTCNews Release: WHO advises not to use non-sugar sweeteners for weight control in newly released guideline – World Health Organization
WHO Guideline: Use of non-sugar sweeteners – World Health Organization
Meta-Analysis: Health effects of the use of non-sugar sweeteners – World Health Organization
Canadian Task Force advises fragility fracture screening for women over 65, but not for men or younger women
15 May, 2023 | 13:23h | UTCRelated USPSTF Statement: Screening Osteoporosis to Prevent Fractures
RCT | Statins do not prevent early cardiac dysfunction in anthracycline-treated cancer patients
15 May, 2023 | 13:07h | UTCStatins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines – European Heart Journal – Cardiovascular Pharmacotherapy (link to abstract – $ for full-text)
Commentary on Twitter
Primary prevention with atorvastatin during anthracycline therapy did not prevent cardiac dysfunction and myocardial tissue changes: SPARE-HF randomized trial https://t.co/9s2p9JSSq4 #echofirst #HF #LVEF #CMR #ESCYoung #EHJPharmacotherapy @FeliceGragnano @AgewallStefan pic.twitter.com/7tKG4tdpcD
— European Society of Cardiology Journals (@ESC_Journals) May 13, 2023
M-A | Adding exercise to hypocaloric diet doesn’t enhance weight loss or glycemic control in T2D patients
15 May, 2023 | 12:52h | UTC
Endocrinopathies from checkpoint inhibitors: incidence, outcomes, and management
12 May, 2023 | 13:36h | UTCRelated:
Aspirin for primary prevention of cardiovascular disease: what do the current USPSTF guidelines say?
11 May, 2023 | 12:11h | UTCOriginal Guideline: USPSTF Recommendation Statement: Aspirin Use to Prevent Cardiovascular Disease.
Related Randomized Trials:
Randomized Trial: Aspirin for Primary Prevention of Cardiovascular Disease
Randomized Trial: Effects of Aspirin for Primary Prevention in Persons with Diabetes
Randomized Trial: Effect of Aspirin on All-Cause Mortality in the Healthy Elderly
Related Meta-Analysis:
Meta-Analysis: Efficacy and Safety of Aspirin for Primary Prevention of Cardiovascular Events
Related Opinions:
Aspirin for Primary Prevention: Is This the End of the Road?
Evidence evolving on aspirin as prevention – ACP Internist
#347 USPSTF Update: Aspirin for Primary Prevention of CVD – The Curbsiders
Review | Perioperative glycemic management in adults presenting for elective cardiac and non-cardiac surgery
11 May, 2023 | 11:54h | UTCRelated:
Guideline Summary: New guidance on the perioperative management of diabetes.
Perioperative Evaluation and Management of Endocrine Disorders – Mayo Clinic Proceedings
FDA warns of use of selective androgen receptor modulators (SARMs) among teens, young adults
10 May, 2023 | 16:00h | UTCCommentaries:
FDA issues warning for bodybuilding products marketed to teens, young adults – AAP News
Young Men Are Using Banned ‘SARM’ Supplements to Bulk Up, With Harmful Results – HealthDay
Guideline | Use of basal insulin in the management of adults with type 2 diabetes
10 May, 2023 | 15:30h | UTCRelated: Guideline | ADA 2023 Standards of Medical Care in Diabetes.